Odimune 200 mg, 300 mg, 600 mg FC tablets.
PDF Leaflet Revision Date: 23 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults.
Dosage (summary)
One tablet orally once daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- Astemizole
- Bepridil
- Cisapride
- Midazolam
- Voriconazole
- St. John's wort
Contraindications
- Hypersensitivity to components
- Moderate to severe renal impairment
- Pregnancy
- Breastfeeding
- Severe hepatic impairment
Common side effects
- Nausea
- Diarrhea
- Rash
- Dizziness
- Fatigue
Counselling Points
- Take on an empty stomach
- Avoid missed doses
- Monitor for psychiatric symptoms
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Serious psychiatric symptoms
Important Disclaimer
The Odimune 200 mg, 300 mg, 600 mg FC tablets. professional information leaflet below is the property of Cipla Medpro Manufacturing and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
